Yuewei Medical completes nearly 100 million Series B financing, continues to strengthen cardiovascular surgery portfolio

Yuewei Medical announced the completion of an equity financing round of nearly 100 million. This round was led by Efung Capital, with participation from Beishang Capital and Bohai Chuangfu. WinX Capital served as the exclusive financial advisor.

This marks the second substantial financing completed by Yuewei Medical within the year, fully demonstrating the capital market's high recognition of Yuewei Medical's development progress. Empowered by this round of financing, Yuewei Medical will continue to comprehensively strengthen its capabilities in R&D innovation and market penetration within the field of cardiovascular surgery and other extended areas, further consolidating its leading position.

Founded in September 2021 and headquartered in Beijing, Yuewei Medical leverages its founding team's extensive clinical experience to identify clinical needs. By integrating the current development status of related fields, Yuewei Medical has developed multiple medical devices that are global firsts, China firsts, or fill market gaps. Currently, it has two self-developed product lines: Coronary Surgery, and Critical Care & Extracorporeal Circulation, comprising nearly 10 products. Among them, the Ultrasonic Vessel Flow Measurement System, Pulsatile Left Ventricular Assist System, and Dual-Lumen Jugular Vein Cannula are all pioneering products in China.

While deepening its main business and solidifying its core competitive advantages, Yuewei Medical possesses robust capabilities for business extension and M&A integration. In 2025, Yuewei Medical expanded into a Deep Vein Thrombosis (DVT) product line through acquisition, which includes two innovative medical devices. Both devices have entered the registration clinical trial stage, further strengthening Yuewei Medical's leading position within the industry.